Market Overview:
The global etodolac market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of arthritis, increasing awareness about pain management, and growing demand for generic drugs. By type, the market is segmented into tablets and capsules. The tablets segment is expected to dominate the global etodolac market during the forecast period owing to their high demand and widespread use. By application, the market is divided into rheumatoid arthritis (RA), osteoarthritis (OA), mild-to-moderate pain, and other applications. RA dominates the application segment owing to its high prevalence rate across all regions studied in this research study.
Product Definition:
Etodolac is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation.
Tablets:
Tablets are small blocks or capsules containing the active ingredient. They come in different forms such as film, enteric-coated, and effervescent. The choice of a tablet depends on the form of administration that is most convenient for the patient as well as for the physician.
Capsules:
Capsules are small containers made from gelatin that is used to contain drugs for oral administration. They offer several advantages such as protection of the drug, improved taste and flavor, extended shelf life and ease in consumption. The most commonly used material for capsule production is gelatin; however, it can be manufactured using other materials including microcrystalline cellulose (MCC), ethylcellulose and hydroxypropyl methyl cellulose (HPMC).
Application Insights:
Rheumatoid arthritis held the largest market share in 2017. The disease is characterized by inflammation of the lining of the joints and bone erosion. According to a study published in 2018 by Arthritis Research UK, around 54 million people across Europe are affected with rheumatoid arthritis, which is expected to increase with aging and lead towards a rise in demand for etodolac tablets over the forecast period.
The osteoarthritis segment is also expected to grow at lucrative CAGR during the forecast period due to high awareness about pain management among patients suffering from this condition coupled with rising usage of non-steroidal anti-inflammatory drugs (NSAIDs) for pain management owing to their fewer side effects as comparedto other drugs used for this purpose such as acetaminophen or aspirin.
Other applications include acute pain following surgery, dental/gum aches, sprains.
Regional Analysis:
North America dominated the global market in 2017 owing to the high prevalence of rheumatoid arthritis and osteoarthritis. According to a study conducted by National Center for Health Statistics, in U.S., around 13% of adults were suffering from RA and about 2 million people were diagnosed with osteoarthritis each year. Moreover, increasing healthcare expenditure coupled with rising adoption of new technologies is also expected to drive regional demand over the forecast period.
Asia Pacific is expected to be one of the fastest-growing regions due to growing geriatric population base and improving economic conditions in emerging countries such as China & India that are majorly driven by rapid industrialization & urbanization resulting into increased disposable income which has led towards an increase in consumerism triggering product demand for various chronic diseases such as joint pain & inflammation. In addition, favorable government initiatives pertaining political instability along with low manufacturing cost will further boost regional growth over next eight years (2030).
Growth Factors:
- Increasing geriatric population: The global geriatric population is expected to grow at a CAGR of around 7% during the forecast period. This will lead to an increase in the number of people suffering from chronic diseases such as arthritis, which will subsequently drive the demand for etodolac products.
- Rising awareness about pain relief medications: There has been a rise in awareness about various pain relief medications available in the market, which is expected to boost the demand for etodolac products over the next few years.
- Growing prevalence of arthritis: Arthritis is one of the most common chronic diseases and its prevalence is increasing rapidly across all regions worldwide. This will create a high demand for effective pain relief therapies such as etodolac, thereby driving its market growth.
- Technological advancements in drug delivery systems: The development of novel drug delivery systems has led to an increase in patient compliance rates and improved therapeutic outcomes with respect to various drugs including etodolac products .This is likely to fuel market growth over the next few years . 5) Availability of generic versions: A large number of generic versions are available for etodolac products, which helps reduce their overall cost and makes them more affordable for consumers
Scope Of The Report
Report Attributes
Report Details
Report Title
Etodolac Market Research Report
By Type
Tablets, Capsules
By Application
Rheumatoid Arthritis, Osteoarthritis, Mild to Moderate Pain, Other
By Companies
Amneal Pharmaceuticals, Genpharm Ulc, Physicians Total Care, Actavis Elizabeth , Blenheim Pharmacal, Teva , Taro Pharmaceuticals , Apotex, PD-Rx Pharmaceuticals, Nucare Pharmaceuticals, Eon Labs
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Etodolac Market Report Segments:
The global Etodolac market is segmented on the basis of:
Types
Tablets, Capsules
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Rheumatoid Arthritis, Osteoarthritis, Mild to Moderate Pain, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amneal Pharmaceuticals
- Genpharm Ulc
- Physicians Total Care
- Actavis ElizabethÂ
- Blenheim Pharmacal
- TevaÂ
- Taro PharmaceuticalsÂ
- Apotex
- PD-Rx Pharmaceuticals
- Nucare Pharmaceuticals
- Eon Labs
Highlights of The Etodolac Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tablets
- Capsules
- By Application:
- Rheumatoid Arthritis
- Osteoarthritis
- Mild to Moderate Pain
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Etodolac Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) that is used to relieve pain and inflammation. It is available in tablet, oral suspension, and injection forms. Etodolac works by blocking the production of prostaglandins, which are chemicals that cause pain and inflammation.
Some of the major companies in the etodolac market are Amneal Pharmaceuticals, Genpharm Ulc, Physicians Total Care, Actavis Elizabeth‚Â , Blenheim Pharmacal, Teva‚Â , Taro Pharmaceuticals‚Â , Apotex, PD-Rx Pharmaceuticals, Nucare Pharmaceuticals, Eon Labs.
The etodolac market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Etodolac Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Etodolac Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Etodolac Market - Supply Chain
4.5. Global Etodolac Market Forecast
4.5.1. Etodolac Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Etodolac Market Size (000 Units) and Y-o-Y Growth
4.5.3. Etodolac Market Absolute $ Opportunity
5. Global Etodolac Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Etodolac Market Size and Volume Forecast by Type
5.3.1. Tablets
5.3.2. Capsules
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Etodolac Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Etodolac Market Size and Volume Forecast by Application
6.3.1. Rheumatoid Arthritis
6.3.2. Osteoarthritis
6.3.3. Mild to Moderate Pain
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Etodolac Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Etodolac Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Etodolac Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Etodolac Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Etodolac Demand Share Forecast, 2019-2026
9. North America Etodolac Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Etodolac Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Etodolac Market Size and Volume Forecast by Application
9.4.1. Rheumatoid Arthritis
9.4.2. Osteoarthritis
9.4.3. Mild to Moderate Pain
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Etodolac Market Size and Volume Forecast by Type
9.7.1. Tablets
9.7.2. Capsules
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Etodolac Demand Share Forecast, 2019-2026
10. Latin America Etodolac Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Etodolac Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Etodolac Market Size and Volume Forecast by Application
10.4.1. Rheumatoid Arthritis
10.4.2. Osteoarthritis
10.4.3. Mild to Moderate Pain
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Etodolac Market Size and Volume Forecast by Type
10.7.1. Tablets
10.7.2. Capsules
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Etodolac Demand Share Forecast, 2019-2026
11. Europe Etodolac Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Etodolac Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Etodolac Market Size and Volume Forecast by Application
11.4.1. Rheumatoid Arthritis
11.4.2. Osteoarthritis
11.4.3. Mild to Moderate Pain
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Etodolac Market Size and Volume Forecast by Type
11.7.1. Tablets
11.7.2. Capsules
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Etodolac Demand Share, 2019-2026
12. Asia Pacific Etodolac Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Etodolac Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Etodolac Market Size and Volume Forecast by Application
12.4.1. Rheumatoid Arthritis
12.4.2. Osteoarthritis
12.4.3. Mild to Moderate Pain
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Etodolac Market Size and Volume Forecast by Type
12.7.1. Tablets
12.7.2. Capsules
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Etodolac Demand Share, 2019-2026
13. Middle East & Africa Etodolac Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Etodolac Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Etodolac Market Size and Volume Forecast by Application
13.4.1. Rheumatoid Arthritis
13.4.2. Osteoarthritis
13.4.3. Mild to Moderate Pain
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Etodolac Market Size and Volume Forecast by Type
13.7.1. Tablets
13.7.2. Capsules
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Etodolac Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Etodolac Market: Market Share Analysis
14.2. Etodolac Distributors and Customers
14.3. Etodolac Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Amneal Pharmaceuticals
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Genpharm Ulc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Physicians Total Care
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Actavis Elizabeth
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Blenheim Pharmacal
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Teva
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Taro Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Apotex
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. PD-Rx Pharmaceuticals
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Nucare Pharmaceuticals
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Eon Labs
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook